33,348 Shares in Henry Schein, Inc. (NASDAQ:HSIC) Bought by Worldquant Millennium Advisors LLC

Worldquant Millennium Advisors LLC acquired a new position in shares of Henry Schein, Inc. (NASDAQ:HSIC - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 33,348 shares of the company's stock, valued at approximately $2,308,000.

Other large investors have also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC lifted its stake in Henry Schein by 23.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 759 shares of the company's stock valued at $52,000 after buying an additional 143 shares in the last quarter. Guggenheim Capital LLC increased its stake in shares of Henry Schein by 2.5% in the 4th quarter. Guggenheim Capital LLC now owns 6,428 shares of the company's stock valued at $445,000 after acquiring an additional 159 shares during the last quarter. CIBC Asset Management Inc increased its stake in Henry Schein by 1.0% during the 4th quarter. CIBC Asset Management Inc now owns 17,849 shares of the company's stock worth $1,235,000 after purchasing an additional 169 shares in the last quarter. Metis Global Partners LLC boosted its position in Henry Schein by 4.7% during the 4th quarter. Metis Global Partners LLC now owns 4,203 shares of the company's stock worth $291,000 after acquiring an additional 187 shares during the last quarter. Finally, Sanctuary Advisors LLC boosted its holdings in shares of Henry Schein by 5.0% in the 4th quarter. Sanctuary Advisors LLC now owns 4,253 shares of the company's stock valued at $294,000 after buying an additional 203 shares during the last quarter. 96.62% of the stock is currently owned by institutional investors.

Henry Schein Stock Down 0.2%

NASDAQ HSIC traded down $0.14 during trading hours on Wednesday, hitting $73.52. The company had a trading volume of 188,634 shares, compared to its average volume of 1,657,396. Henry Schein, Inc. has a fifty-two week low of $60.56 and a fifty-two week high of $82.49. The company has a market capitalization of $8.95 billion, a price-to-earnings ratio of 30.25, a P/E/G ratio of 2.13 and a beta of 0.87. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82. The firm's 50 day moving average is $67.54 and its 200 day moving average is $71.58.

Henry Schein (NASDAQ:HSIC - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.11 by $0.04. The firm had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.24 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The firm's revenue for the quarter was down .1% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.10 EPS. Sell-side analysts anticipate that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Insider Activity at Henry Schein

In other news, CEO Bradford C. Connett sold 4,036 shares of the business's stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $71.15, for a total value of $287,161.40. Following the transaction, the chief executive officer now directly owns 62,688 shares of the company's stock, valued at $4,460,251.20. The trade was a 6.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Philip A. Laskawy sold 2,604 shares of the stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total value of $184,988.16. Following the completion of the transaction, the director now directly owns 24,805 shares in the company, valued at approximately $1,762,147.20. This trade represents a 9.50% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.14% of the company's stock.

Wall Street Analyst Weigh In

HSIC has been the subject of a number of research reports. Wells Fargo & Company dropped their target price on shares of Henry Schein from $80.00 to $75.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. UBS Group cut their price objective on Henry Schein from $83.00 to $80.00 and set a "neutral" rating for the company in a report on Wednesday, February 26th. Piper Sandler decreased their target price on Henry Schein from $83.00 to $77.00 and set an "overweight" rating for the company in a report on Wednesday, April 30th. Barrington Research decreased their price objective on Henry Schein from $90.00 to $86.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. Finally, Wall Street Zen downgraded Henry Schein from a "buy" rating to a "hold" rating in a research note on Thursday, April 17th. Six equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Henry Schein currently has a consensus rating of "Moderate Buy" and an average target price of $79.30.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.